Mer­ck re­ports an­oth­er fail­ure for Keytru­da-Lyn­parza com­bo in non-small cell lung can­cer

Mer­ck has once again failed to boost the ef­fects of its PD-1 block­buster Keytru­da by adding As­traZeneca’s PARP in­hibitor Lyn­parza.

When giv­en as a main­te­nance ther­a­py, Lyn­parza and Keytru­da did not re­sult in sur­vival ben­e­fits for cer­tain first-line non­squa­mous non-small cell lung can­cer (NSCLC) pa­tients com­pared to Keytru­da and peme­trexed, a type of chemother­a­py. The com­bo al­so failed to meet its sec­ond pri­ma­ry end­point, pro­gres­sion-free sur­vival, Mer­ck an­nounced Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER